Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 55

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 55
---
.

We entered into an employment agreement with Dr. Koehler in April 2019, effective May 1, 2019 in connection with her appointment as our Executive Vice President, Chief Medical Officer. In June 2020, we entered into a new employment agreement with Dr. Koehler which became effective upon the execution of the underwriting agreement for our IPO. Pursuant to her June 2020 employment agreement, Dr. Koehler was initially entitled to an annual base salary of $415,000, an annual target bonus with a target amount equal to 40% of her annual base salary and certain severance benefits, as described below under “—Potential Payments and Benefits upon Termination or Change of Control.” Dr. Koehler was also eligible for additional equity awards under our equity compensation plans, as may be granted from time to time. In July 2023, we amended Dr. Koehler’s June 2020 employment agreement to reflect updated termination of employment and change in control provisions to cover granted RSU awards.

Koehler Separation Agreement. In connection with Dr. Koehler’s separation from employment as our Executive Vice-President, Chief Medical Officer, effective March 31, 2025, we and Dr. Koehler entered into a separation agreement, dated February 24, 2025, providing for the terms of Dr. Koehler’s separation from employment. Under the terms of Dr. Koehler’s separation agreement, we have provided and will provide Dr. Koehler with the following separation payments and benefits: (i) a lump sum payment of $378,750 less applicable deductions and withholdings, representing nine months of Dr. Koehler’s base salary; (ii) an additional lump sum payment of $150,000, which was contingent upon her continuous service with the Company through March 31, 2025; (iii) an additional cash payment of $86,250, representing the remaining 75% installment of the cash retention bonus awarded to her in August 2024, payable on May 31, 2025, which is contingent upon her providing consulting services for three months following the effective date of her separation; (iv) continued payment of the employer portions of Dr. Koehler’s COBRA health insurance premiums for up to 12 months; and (v) the vesting of all unvested option awards and restricted stock unit awards that are subject to a time-based vesting schedule, on a prorated basis, were accelerated as if Dr. Koehler had remained